JP2018526351A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526351A5
JP2018526351A5 JP2018506262A JP2018506262A JP2018526351A5 JP 2018526351 A5 JP2018526351 A5 JP 2018526351A5 JP 2018506262 A JP2018506262 A JP 2018506262A JP 2018506262 A JP2018506262 A JP 2018506262A JP 2018526351 A5 JP2018526351 A5 JP 2018526351A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
solid solution
solution pharmaceutical
composition according
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526351A (ja
JP6989489B2 (ja
Filing date
Publication date
Priority claimed from US14/821,687 external-priority patent/US9744132B2/en
Priority claimed from EP15180256.8A external-priority patent/EP3127556A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/068900 external-priority patent/WO2017025517A1/en
Publication of JP2018526351A publication Critical patent/JP2018526351A/ja
Publication of JP2018526351A5 publication Critical patent/JP2018526351A5/ja
Application granted granted Critical
Publication of JP6989489B2 publication Critical patent/JP6989489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506262A 2015-08-07 2016-08-08 Nsaidのための固溶体組成物 Active JP6989489B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/821,687 2015-08-07
US14/821,687 US9744132B2 (en) 2010-10-29 2015-08-07 Solid solution compositions and use in chronic inflammation
EP15180256.8 2015-08-07
EP15180256.8A EP3127556A1 (en) 2015-08-07 2015-08-07 Solid solution compositions for nsaid
PCT/EP2016/068900 WO2017025517A1 (en) 2015-08-07 2016-08-08 SOLID SOLUTION COMPOSITIONS FOR NSAIDs

Publications (3)

Publication Number Publication Date
JP2018526351A JP2018526351A (ja) 2018-09-13
JP2018526351A5 true JP2018526351A5 (enExample) 2019-09-12
JP6989489B2 JP6989489B2 (ja) 2022-01-05

Family

ID=56800263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506262A Active JP6989489B2 (ja) 2015-08-07 2016-08-08 Nsaidのための固溶体組成物

Country Status (10)

Country Link
EP (2) EP3988091B1 (enExample)
JP (1) JP6989489B2 (enExample)
CN (1) CN108025078A (enExample)
AU (1) AU2016306610B2 (enExample)
CA (1) CA2994899C (enExample)
ES (1) ES2906571T3 (enExample)
IL (1) IL257385A (enExample)
MX (1) MX387217B (enExample)
PL (1) PL3331568T3 (enExample)
WO (1) WO2017025517A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
WO2022207580A2 (en) 2021-03-27 2022-10-06 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US10695432B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
PL3795141T3 (pl) * 2013-01-14 2025-11-12 Infirst Healthcare Limited Kompozycje w postaci roztworu stałego

Similar Documents

Publication Publication Date Title
JP2018526351A5 (enExample)
JP2016504401A5 (enExample)
JP2016506941A5 (enExample)
JP2016504403A5 (enExample)
MX387217B (es) Composiciones de solución sólida para aines.
EP3355874A4 (en) TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF
JP2017105763A5 (enExample)
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
RU2017115772A (ru) Комбинация для генотерапии
FR3024037B1 (fr) Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA202192322A1 (ru) Фармацевтические составы
MA39443A1 (fr) Nouvelle formulation de méloxicam
MX386521B (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
EA202091603A1 (ru) Фармацевтические композиции на основе ментилового эфира индометацина и их применение в качестве противовоспалительных средств
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
EP3435990A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS FOR TOPICAL ADMINISTRATION AND USES THEREOF
RU2015121239A (ru) Комбинированная фармацевтическая композиция для лечения болевых синдромов
RU2017113827A (ru) Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения
MX386932B (es) Proceso para formulaciones sólidas de mesalazina.
MX2013008993A (es) Sistema de liberacion modificada en tres fases de un antiinflamatorio no esteroide.
EA201790089A1 (ru) Фармацевтические средства для лечения головокружения различной этиологии